Fluorine in medicinal chemistry.

Since its first use in the steroid field in the late 1950s, the use of fluorine in medicinal chemistry has become commonplace, with the small electronegative fluorine atom being a key part of the medicinal chemist's repertoire of substitutions used to modulate all aspects of molecular properties including potency, physical chemistry and pharmacokinetics. This review will highlight the special nature of fluorine, drawing from a survey of marketed fluorinated pharmaceuticals and the medicinal chemistry literature, to illustrate key concepts exploited by medicinal chemists in their attempts to optimize drug molecules. Some of the potential pitfalls in the use of fluorine will also be highlighted.

[1]  N. Thornberry,et al.  Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). , 2007, Bioorganic & medicinal chemistry letters.

[2]  Anna Vulpetti,et al.  Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. , 2009, Journal of the American Chemical Society.

[3]  John Sharkey,et al.  Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.

[4]  C. Stout,et al.  The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Bruce E. Smart,et al.  Fluorine substituent effects (on bioactivity) , 2001 .

[6]  I. Hayakawa,et al.  (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. , 1994, Journal of medicinal chemistry.

[7]  A. Vulpetti,et al.  Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations. , 2014, Chemistry.

[8]  Guangtao Li,et al.  Palladium‐Catalyzed CF Bond Formation via Directed CH Activation , 2014 .

[9]  Varinder K. Aggarwal,et al.  Science of Synthesis , 2005 .

[10]  J. Ponto The Handbook of Radiopharmaceuticals , 1996 .

[11]  D. Halpern Fluorinated Inhalation Anesthetics , 1994 .

[12]  Chun Xing Li,et al.  Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding. , 2002, Bioorganic & medicinal chemistry letters.

[13]  J. B. Buckton,et al.  Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates. , 1994, Journal of medicinal chemistry.

[14]  C. Swain,et al.  Piperidine-ether based hNK1 antagonists 1: Determination of the relative and absolute stereochemical requirements , 1994 .

[15]  N. Thornberry,et al.  Chapter 7 Case History: JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes , 2007 .

[16]  A. Bell,et al.  Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus , 1996 .

[17]  Alan Wheeldon,et al.  1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[18]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[19]  P. Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.

[20]  A. Slawin,et al.  3-Fluoro-N-methyl-D-aspartic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors. , 2012, Chemistry.

[21]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[22]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[23]  E. Carreira,et al.  On the polarity of partially fluorinated methyl groups , 2013 .

[24]  N. Jackson,et al.  Special Feature Organo-Fluorine Chemical Science , 2012 .

[25]  M. Sweeney,et al.  Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials , 2007, Expert opinion on drug metabolism & toxicology.

[26]  D. Hodgson,et al.  Sodium monofluoroacetate (Compound 1080) poisoning in dogs. , 2005, Australian veterinary journal.

[27]  H. Rzepa,et al.  The preferred conformation of α-fluoroamides , 1999 .

[28]  M. Rowley 3‐(4‐Fluoropiperidin‐3‐yl)‐2‐phenylindoles as High Affinity, Selective, and Orally Bioavailable h5‐HT2A Receptor Antagonists. , 2001 .

[29]  Steven V. Fox,et al.  Pyridyl amides as potent inhibitors of T-type calcium channels. , 2011, Bioorganic & medicinal chemistry letters.

[30]  Ramesh Kakarla,et al.  Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. , 2014, Journal of medicinal chemistry.

[31]  P. Noakes,et al.  The mode of toxic action of the pesticide Gliftor: The metabolism of 1,3‐difluoroacetone to (−)‐erythro‐fluorocitrate , 2001, Journal of biochemical and molecular toxicology.

[32]  J. Howard,et al.  Synthesis of monofluoro- and difluoro- methylenephosphonate analogues of sn-glycerol-3-phosphate as substrates for glycerol-3-phosphate dehydrogenase and the X-ray structure of the fluoromethylenephosphonate moiety , 1996 .

[33]  A. Aronov Ligand structural aspects of hERG channel blockade. , 2008, Current topics in medicinal chemistry.

[34]  Shinji Tanaka,et al.  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models. , 2011, Bioorganic & medicinal chemistry letters.

[35]  You-Jung Park,et al.  Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[36]  M. Wilson,et al.  Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. , 1990, Journal of medicinal chemistry.

[37]  Hanna Wójtowicz-Rajchel Synthesis and applications of fluorinated nucleoside analogues , 2012 .

[38]  C. K. Chu,et al.  Fluorinated Nucleosides: Synthesis and Biological Implication. , 2008, Journal of fluorine chemistry.

[39]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[40]  Alexander G. Dossetter,et al.  A matched molecular pair analysis of in vitro human microsomal metabolic stability measurements for heterocyclic replacements of di-substituted benzene containing compounds – identification of those isosteres more likely to have beneficial effects , 2012 .

[41]  D G Reid,et al.  Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase. , 1991, European journal of biochemistry.

[42]  Wolfgang Guba,et al.  β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[43]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[44]  Marc C Nicklaus,et al.  Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. , 2004, Journal of the American Chemical Society.

[45]  E. Stefánsson,et al.  Topical drug delivery to the eye: dorzolamide , 2012, Acta ophthalmologica.

[46]  A. Vulpetti,et al.  Fluorine local environment: from screening to drug design. , 2012, Drug discovery today.

[47]  J. Clader,et al.  Discovery of 1‐(4‐Fluorophenyl)‐(3R)‐ [3‐(4‐fluorophenyl)‐(3S)‐hydroxypropyl] ‐(4S)‐(4‐hydroxyphenyl)‐2‐azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption. , 1998 .

[48]  T. Maren,et al.  A new class of carbonic anhydrase inhibitor. , 1993, The Journal of biological chemistry.

[49]  C. Eason,et al.  A 90-day toxicological evaluation of Compound 1080 (sodium monofluoroacetate) in Sprague-Dawley rats. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  C. George,et al.  Comprehensive structural studies of 2',3'-difluorinated nucleosides: comparison of theory, solution, and solid state. , 2008, Journal of the American Chemical Society.

[51]  P. Kirkpatrick,et al.  Fresh from the pipeline. Ezetimibe. , 2003, Nature reviews. Drug discovery.

[52]  N. Wood,et al.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[53]  J. Humphrey Medicinal chemistry of selective neurokinin-1 antagonists. , 2003, Current topics in medicinal chemistry.

[54]  S. Harding The human pharmacology of fluticasone propionate. , 1990, Respiratory medicine.

[55]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[56]  R. Young,et al.  Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[57]  G. Colombo,et al.  Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. , 2003, Chemistry.

[58]  David J. Yang,et al.  Handbook of Radiopharmaceuticals: Radiochemistry and Applications , 2004 .

[59]  Choon‐Hong Tan,et al.  Selective fluorination of alkyl C-H bonds via photocatalysis. , 2014, Chemical communications.

[60]  François Diederich Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities , 2007 .

[61]  Martin Stahl,et al.  Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.

[62]  M. Otto,et al.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.

[63]  H. Böhm,et al.  Facilitating the Design of Fluorinated Drugs , 2009 .

[64]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[65]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[66]  W. Zeng,et al.  Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers , 2007, Biopharmaceutics & drug disposition.

[67]  Youwei Yan,et al.  Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. , 2008, Journal of medicinal chemistry.

[68]  J. Domagala,et al.  New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.

[69]  Carlos González,et al.  Rigid 2',4'-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase. , 2014, The Journal of organic chemistry.

[70]  Steven D. Brown,et al.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species , 1996, Antimicrobial agents and chemotherapy.

[71]  C. Supuran,et al.  New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[72]  G. H. Phillipps Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. , 1990, Respiratory medicine.

[73]  F. R E D E R I C,et al.  TOXICITY AND ACTION OF FLUENETHYL ACARICIDE AND RELATED COMPOUNDS IN THE MOUSE , HOUSEFLY AND TWOSPOTTED SPIDER MITE , 2022 .

[74]  Niklas Blomberg,et al.  Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. , 2011, Bioorganic & medicinal chemistry letters.

[75]  Desmond O'Connor,et al.  4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia. , 2005, Bioorganic & medicinal chemistry letters.

[76]  B. Zhong,et al.  Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. , 2001, Journal of the American Chemical Society.

[77]  Guangtao Li,et al.  Palladium‐Catalyzed C—F Bond Formation via Directed C—H Activation , 2014 .

[78]  J. Kath,et al.  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. , 2004, Bioorganic & medicinal chemistry letters.

[79]  A. Slawin,et al.  Synthesis and Vanilloid Receptor (TRPV1) Activity of the Enantiomers of α‐Fluorinated Capsaicin , 2009, ChemBioChem.

[80]  Victor E. Marquez,et al.  HIV-1 REVERSE TRANSCRIPTASE CAN DISCRIMINATE BETWEEN TWO CONFORMATIONALLY LOCKED CARBOCYCLIC AZT TRIPHOSPHATE ANALOGUES , 1998 .

[81]  S. Dworetzky,et al.  Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. , 2003, Journal of medicinal chemistry.

[82]  H. Davis,et al.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.

[83]  A. Robichaud,et al.  The next generation of PDE4 inhibitors. , 2001, Current opinion in chemical biology.

[84]  C. D. Boone,et al.  Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. , 2013, Bioorganic & medicinal chemistry.

[85]  Jeremy N. Burrows,et al.  Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors , 2014, Journal of medicinal chemistry.

[86]  B. Matuszewski,et al.  Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. , 2004, Journal of pharmaceutical and biomedical analysis.

[87]  C. Swain,et al.  Piperidine-ether based hNK1 antagonists 2: Investigation of the effect of N-substitution , 1995 .

[88]  Peter W. Kenny,et al.  Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis , 1994 .

[89]  David A. Price,et al.  Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks , 2010 .

[90]  J. Falgueyret,et al.  Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. , 2005, Bioorganic & medicinal chemistry letters.

[91]  Z. Parandoosh,et al.  Interaction of glucocorticoid analogues with the human glucocorticoid receptor , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[92]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[93]  K. Richardson The discovery of fluconazole , 1996 .

[94]  Daniel Oehlrich,et al.  The evolution of amidine-based brain penetrant BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[95]  A. Liljas,et al.  The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide , 1994, FEBS letters.

[96]  C. Bayly,et al.  Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. , 2006, Bioorganic & Medicinal Chemistry Letters.

[97]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[98]  E. F. Sabo,et al.  9α-FLUORO DERIVATIVES OF CORTISONE AND HYDROCORTISONE , 1954 .

[99]  M. Palem-Vliers,et al.  Role of hydrophobic effects and polar groups in steroid-mineralocorticoid receptor interactions. , 1983, Journal of steroid biochemistry.

[100]  Bernd Kuhn,et al.  Molecular recognition of ligands in dipeptidyl peptidase IV. , 2007, Current topics in medicinal chemistry.

[101]  Chuo Chen,et al.  Vanadium-Catalyzed C(sp3)-H Fluorination Reactions. , 2014, Organic chemistry frontiers : an international journal of organic chemistry.

[102]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[103]  K. Ding,et al.  Organic chemistry : breakthroughs and perspectives , 2012 .

[104]  B. Jönsson,et al.  Pharmacoeconomics , 2018, Indian Journal of Medical and Paediatric Oncology.

[105]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[106]  C. R. Briggs,et al.  The CF bond as a tool in the conformational control of amides , 2003 .

[107]  A. Robichaud,et al.  The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[108]  D. O'Hagan Understanding Organofluorine Chemistry. An Introduction to the C—F Bond , 2008 .

[109]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[110]  C. Swain,et al.  Phenyl-glycinol based NK1 receptor antagonists — towards the minimum pharmacophore , 1995 .

[111]  B. Graves,et al.  Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors , 2011, Journal of medicinal chemistry.

[112]  Organofluorine Chemistry: Deoxyfluorination Reagents for C—F Bond Synthesis , 2012 .

[113]  François Diederich,et al.  Orthogonal multipolar interactions in structural chemistry and biology. , 2005, Angewandte Chemie.

[114]  J. Metzger,et al.  Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. , 1998, Journal of medicinal chemistry.

[115]  C. Strader,et al.  2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. , 1996, Journal of medicinal chemistry.

[116]  A. MacGowan,et al.  Development of the quinolones. , 2003, The Journal of antimicrobial chemotherapy.

[117]  W. L. Mock,et al.  Concerning the relative acidities of simple alcohols , 1990 .

[118]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[119]  Richard I. Hartley,et al.  Chirality , 2004, International Journal of Computer Vision.

[120]  R. Chambers,et al.  Fluorine in organic chemistry , 1973 .

[121]  L. Hunter,et al.  The C–F bond as a conformational tool in organic and biological chemistry , 2010, Beilstein journal of organic chemistry.

[122]  D. Ehmann,et al.  Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile. , 2012, Journal of medicinal chemistry.

[123]  G. Prakash,et al.  Flourishing Frontiers in Organofluorine Chemistry , 2012 .

[124]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[125]  A. Asai,et al.  Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. , 2010, Journal of medicinal chemistry.

[126]  Keith H. Gibson and Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer. , 2010 .

[127]  P. Hajduk,et al.  Statistical analysis of the effects of common chemical substituents on ligand potency. , 2008, Journal of medicinal chemistry.

[128]  N. Thornberry,et al.  Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[129]  D. Tashkin Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD , 2014, Expert opinion on pharmacotherapy.

[130]  Alexander G. Dossetter,et al.  A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series. , 2010, Bioorganic & medicinal chemistry.

[131]  P. L. McCormack Celecoxib , 2011, Drugs.

[132]  Jimmy Wu Review of recent advances in nucleophilic C–F bond-forming reactions at sp3 centers , 2014 .